| Hormone receptor positive breast cancer
Afinitor vs Trodelvy
Side-by-side clinical, coverage, and cost comparison for hormone receptor positive breast cancer.Deep comparison between: Afinitor vs Trodelvy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrodelvy has a higher rate of injection site reactions vs Afinitor based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trodelvy but not Afinitor, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Afinitor
Trodelvy
At A Glance
Oral
Daily
mTOR inhibitor
IV infusion
Once weekly (Days 1 and 8 of 21-day cycles)
Trop-2-directed antibody-drug conjugate
Indications
- Hormone receptor positive breast cancer
- Neuroendocrine tumor of pancreas
- Gastro-enteropancreatic neuroendocrine tumor
- Renal Cell Carcinoma
- Angiomyolipoma of kidney
- Subependymal Giant Cell Astrocytoma
- Seizures, Focal
- Triple Negative Breast Neoplasms
- Hormone receptor positive breast cancer
Dosing
Hormone receptor positive breast cancer 10 mg orally once daily in combination with exemestane until disease progression or unacceptable toxicity.
Neuroendocrine tumor of pancreas, Gastro-enteropancreatic neuroendocrine tumor 10 mg orally once daily until disease progression or unacceptable toxicity.
Renal Cell Carcinoma 10 mg orally once daily until disease progression or unacceptable toxicity.
Angiomyolipoma of kidney 10 mg orally once daily until disease progression or unacceptable toxicity.
Subependymal Giant Cell Astrocytoma Starting dose 4.5 mg/m2 orally once daily (AFINITOR or AFINITOR DISPERZ); titrate to trough concentration 5-15 ng/mL.
Seizures, Focal Starting dose 5 mg/m2 orally once daily (AFINITOR DISPERZ); titrate to trough concentration 5-15 ng/mL.
Triple Negative Breast Neoplasms, Hormone receptor positive breast cancer 10 mg/kg IV infusion once weekly on Days 1 and 8 of 21-day treatment cycles until disease progression or unacceptable toxicity; first infusion over 3 hours, subsequent infusions over 1 to 2 hours if prior infusions were tolerated.
Contraindications
- Clinically significant hypersensitivity to everolimus or other rapamycin derivatives
- Previous severe hypersensitivity reaction to TRODELVY
Adverse Reactions
Most common (>=30%) Stomatitis, infections, rash, fatigue, diarrhea, decreased appetite.
Serious Non-infectious pneumonitis, infections, severe hypersensitivity reactions, angioedema, stomatitis, renal failure, impaired wound healing, metabolic disorders (hyperglycemia, dyslipidemia), myelosuppression, radiation sensitization and recall.
Postmarketing Thrombotic microangiopathy, cardiac failure (including with pulmonary hypertension), acute pancreatitis, cholecystitis, cholelithiasis, sepsis, reflex sympathetic dystrophy, arterial thrombotic events, lymphedema, radiation sensitization and recall.
Most common (>=25%) Decreased leukocyte count, decreased neutrophil count, decreased hemoglobin, diarrhea, nausea, decreased lymphocyte count, fatigue, alopecia, constipation, increased glucose, decreased albumin, vomiting, decreased appetite, decreased creatinine clearance, increased alkaline phosphatase, decreased magnesium, decreased potassium, decreased sodium
Serious Neutropenia, febrile neutropenia, diarrhea, pneumonia, abdominal pain, colitis, neutropenic colitis, vomiting, respiratory failure, septic shock
Pharmacology
Everolimus is an mTOR inhibitor that binds the intracellular protein FKBP-12 to form an inhibitory complex with mTORC1, suppressing downstream effectors (S6K1, 4E-BP1) involved in protein synthesis, cell proliferation, and angiogenesis, and reducing HIF-1 and VEGF expression; mTOR pathway dysregulation occurs in several human cancers and in tuberous sclerosis complex.
Sacituzumab govitecan-hziy is a Trop-2-directed antibody-drug conjugate in which the humanized anti-Trop-2 antibody sacituzumab delivers SN-38, a topoisomerase I inhibitor, into Trop-2-expressing cancer cells, where SN-38 prevents re-ligation of topoisomerase I-induced single-strand breaks, leading to DNA damage, apoptosis, and cell death.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Afinitor
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
Trodelvy
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Afinitor
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (6/8)
Trodelvy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Afinitor
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Trodelvy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Afinitor.
Cost estimate not availableAssistance Fund: Bladder Cancer (Federal Healthcare Program): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AfinitorView full Afinitor profile
TrodelvyView full Trodelvy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.